+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

SK Chemicals Co Ltd (285130) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 46 Pages
  • July 2026
  • GlobalData
  • ID: 5930747
SK Chemicals Co Ltd (285130) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

SK chemicals Co Ltd (SK Chemicals), a subsidiary of SK Inc, is a chemical manufacturing company. It is primarily engaged in the production and sale of synthetic resins and related products, as well as the development, production, and sales of pharmaceuticals and vaccines. Specialty Polymers (Copolyester), adhesives, coating agents, bio-based material PO3G, CR-PET materials, and CR raw materials such as r-BHET, and new drugs and premium vaccines. Notable brands associated with the company include Skypura, Skypel, Skybon, Skydmt, Ecotria, Ecozen, and Sky Green. The company's products serve various industries, including healthcare and manufacturing, catering to customer needs for sustainable and innovative solutions. SK Chemicals has established a presence through local subsidiaries and regional offices in China, the US, Germany, Japan, and Malaysia. SK Chemicals is headquartered in Ulsan, South Korea.

SK Chemicals Co Ltd Key Recent Developments

  • Feb 06, 2026: SK Chemicals Reports KRW 2.3652 Trillion in 2025 Revenue, Up 36% Year On Year
  • Aug 07, 2025: SK Chemicals Reports First-Half Revenue of KRW 731.1 Billion and Operating Profit of KRW 62.1 Billion
  • Jul 07, 2025: SK Chemicals Publishes “2024 Sustainability Report”
  • May 12, 2025: SK chemicals Delivers “Strong Performance in Q1 Amid Continued Market Downturn” Q1 Operating Profit Reaches KRW 36.9 Billion, Up 98.5% Year-on-Year

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Daewoong Pharmaceutical Co Ltd - Key Facts
  • Daewoong Pharmaceutical Co Ltd - Key Employees
  • Daewoong Pharmaceutical Co Ltd - Key Employee Biographies
  • Daewoong Pharmaceutical Co Ltd - Major Products and Services
  • Daewoong Pharmaceutical Co Ltd - History
  • Daewoong Pharmaceutical Co Ltd - Company Statement
  • Daewoong Pharmaceutical Co Ltd - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
  • Joint Venture
Section 2 - Company Analysis
  • Company Overview
  • Daewoong Pharmaceutical Co Ltd - Business Description
  • Business Segment: Others
  • Performance
  • Business Segment: Pharmaceutical Manufacturing and Sales
  • Performance
  • Business Segment: Service Provision
  • Performance
  • Geographical Segment: Domestic Consumption
  • Performance
  • Geographical Segment: Export
  • Performance
  • R&D Overview
  • Daewoong Pharmaceutical Co Ltd - Corporate Strategy
  • Daewoong Pharmaceutical Co Ltd - SWOT Analysis
  • SWOT Analysis - Overview
  • Daewoong Pharmaceutical Co Ltd - Strengths
  • Daewoong Pharmaceutical Co Ltd - Weaknesses
  • Daewoong Pharmaceutical Co Ltd - Opportunities
  • Daewoong Pharmaceutical Co Ltd - Threats
  • Daewoong Pharmaceutical Co Ltd - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Daewoong Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
  • Daewoong Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
  • Daewoong Pharmaceutical Co Ltd, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Jun 29, 2026: Hanyang University Hospital, First University Hospital in Seoul to Introduce Sink Systems in All Beds
  • Apr 24, 2026: Daewoong Pharmaceutical Hosts ‘NABOTA Master Class’… Highlighting Safety amid Growing Demand for High-Dose, Repetitive Treatments
  • Jan 26, 2026: Daewoong Pharma Expands Cooperation in AI Digital Healthcare, Focusing on Safety, Precision, and Efficiency, in Line With the Advancement of Medical Institutions’ AI Treatment Systems
  • Dec 31, 2025: Daewoong Pharmaceutical Selected as a “Leading Family-Friendly Company” and Demonstrates a “Delightful Workplace” Organizational Culture Based on Autonomy and Growth
  • Dec 17, 2025: Daewoong Pharmaceutical Receives First Health-Friendly Certification "A Company Where Employees Are Happy and Health-Free"
  • Dec 10, 2025: Daewoong Pharmaceutical’s Autoimmune Disease Drug Candidate Selected for the National New Drug Project, Addressing Unmet Needs for Multiple Sclerosis
  • Dec 02, 2025: Energetic During the Day, Comfortable at Night… Daewoong Pharmaceutical Launches a Renewed Version of Its Comprehensive Cold Medicine, “C-Cold Premium Tablets.”
  • Nov 17, 2025: Daewoong Pharmaceutical selected as a research institute for K-AI national project
  • Nov 13, 2025: Pohang Good Sunrin Hospital Becomes First in Daegu and Gyeongbuk to Introduce “Think” Technology to All Its Beds, Leading the Way in Smart Hospitals.
  • Nov 06, 2025: Hwaseong City’s First “AI Smart Ward” Opens... Dongtan City Hospital Accelerates 24-Hour Smart Medical Care With “Think.”
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Analyst
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Daewoong Pharmaceutical Co Ltd, Key Facts
  • Daewoong Pharmaceutical Co Ltd, Key Employees
  • Daewoong Pharmaceutical Co Ltd, Key Employee Biographies
  • Daewoong Pharmaceutical Co Ltd, Major Products and Services
  • Daewoong Pharmaceutical Co Ltd, History
  • Daewoong Pharmaceutical Co Ltd, Other Locations
  • Daewoong Pharmaceutical Co Ltd, Subsidiaries
  • Daewoong Pharmaceutical Co Ltd, Joint Venture
  • Daewoong Pharmaceutical Co Ltd, Key Competitors
  • Daewoong Pharmaceutical Co Ltd, Ratios based on current share price
  • Daewoong Pharmaceutical Co Ltd, Annual Ratios
  • Daewoong Pharmaceutical Co Ltd, Interim Ratios
  • Daewoong Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
  • Daewoong Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
  • Daewoong Pharmaceutical Co Ltd, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Daewoong Pharmaceutical Co Ltd, Performance Chart (2021 - 2025)
  • Daewoong Pharmaceutical Co Ltd, Ratio Charts
  • Daewoong Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
  • Daewoong Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2020 to YTD 2026